GlassScriptPhysician profile
Philip A Cusumano
NPI 1295767572
$357.08
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $61.95 · 2021: $16.81.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $84.79 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.05 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.66 | 2019 | |
| Pfizer INC. | $37.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.11 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $16.93 | 2020 | |
| Indivior INC. | $16.81 | 2021 | |
| Shire North American Group INC | $15.70 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.18 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.96 | 2019 | |
| Allergan, INC. | $14.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Cusumano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.